Loading clinical trials...
Loading clinical trials...
Phase II, Open Label, Single Arm Study of the Efficacy and Safety of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Conditions
Interventions
TQ-B3101
Locations
22
China
Anhui chest hospital
Hefei, Anhui, China
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
Tumor hospital, Chinese academy of medical sciences
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fujian Tumor Hospital
Fuzhou, Fujian, China
Affiliated tumor hospital of sun yat-sen university
Guangzhou, Guangdong, China
Start Date
July 24, 2019
Primary Completion Date
March 1, 2021
Completion Date
March 1, 2021
Last Updated
August 15, 2019
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions